BRCA1 and BRCA2: different roles in a common pathway of genome protection
- PMID: 22193408
- PMCID: PMC4972490
- DOI: 10.1038/nrc3181
BRCA1 and BRCA2: different roles in a common pathway of genome protection
Abstract
The proteins encoded by the two major breast cancer susceptibility genes, BRCA1 and BRCA2, work in a common pathway of genome protection. However, the two proteins work at different stages in the DNA damage response (DDR) and in DNA repair. BRCA1 is a pleiotropic DDR protein that functions in both checkpoint activation and DNA repair, whereas BRCA2 is a mediator of the core mechanism of homologous recombination. The links between the two proteins are not well understood, but they must exist to explain the marked similarity of human cancer susceptibility that arises with germline mutations in these genes. As discussed here, the proteins work in concert to protect the genome from double-strand DNA damage during DNA replication.
Conflict of interest statement
The authors declare no competing financial interests.
Figures
Comment in
-
Initiation, evolution, phenotype and outcome of BRCA1 and BRCA2 mutation-associated breast cancer.Nat Rev Cancer. 2012 May 24;12(5):372-3; author reply 372. doi: 10.1038/nrc3181-c1. Nat Rev Cancer. 2012. PMID: 22525576 No abstract available.
-
BRCA1 and BRCA2: a common pathway of genome protection but different breast cancer subtypes.Nat Rev Cancer. 2012 May 24;12(5):372; author reply 372. doi: 10.1038/nrc3181-c2. Nat Rev Cancer. 2012. PMID: 22525577 No abstract available.
Similar articles
-
PALB2 links BRCA1 and BRCA2 in the DNA-damage response.Curr Biol. 2009 Mar 24;19(6):524-9. doi: 10.1016/j.cub.2009.02.018. Epub 2009 Mar 5. Curr Biol. 2009. PMID: 19268590 Free PMC article.
-
New complexities for BRCA1 and BRCA2.Curr Biol. 2001 Aug 21;11(16):R668-76. doi: 10.1016/s0960-9822(01)00389-x. Curr Biol. 2001. PMID: 11525763 Review.
-
Therapeutic exploitation of tumor cell defects in homologous recombination.Anticancer Agents Med Chem. 2008 May;8(4):448-60. doi: 10.2174/187152008784220267. Anticancer Agents Med Chem. 2008. PMID: 18473729 Review.
-
Hallmarks of 'BRCAness' in sporadic cancers.Nat Rev Cancer. 2004 Oct;4(10):814-9. doi: 10.1038/nrc1457. Nat Rev Cancer. 2004. PMID: 15510162 Review.
-
A BRCA1 Coiled-Coil Domain Variant Disrupting PALB2 Interaction Promotes the Development of Mammary Tumors and Confers a Targetable Defect in Homologous Recombination Repair.Cancer Res. 2021 Dec 15;81(24):6171-6182. doi: 10.1158/0008-5472.CAN-21-1415. Epub 2021 Sep 21. Cancer Res. 2021. PMID: 34548335 Free PMC article.
Cited by
-
Antioxidant Properties of Zinc and Copper-Blood Zinc-to Copper-Ratio as a Marker of Cancer Risk BRCA1 Mutation Carriers.Antioxidants (Basel). 2024 Jul 14;13(7):841. doi: 10.3390/antiox13070841. Antioxidants (Basel). 2024. PMID: 39061909 Free PMC article.
-
Prediction of the treatment response in ovarian cancer: a ctDNA approach.J Ovarian Res. 2020 Oct 19;13(1):124. doi: 10.1186/s13048-020-00729-1. J Ovarian Res. 2020. PMID: 33076944 Free PMC article. Review.
-
Identification of Recurrent Variants in BRCA1 and BRCA2 across Multiple Cancers in the Chinese Population.Biomed Res Int. 2020 Aug 15;2020:6739823. doi: 10.1155/2020/6739823. eCollection 2020. Biomed Res Int. 2020. PMID: 32879886 Free PMC article.
-
BRCA1 Mutations in Cancer: Coordinating Deficiencies in Homologous Recombination with Tumorigenesis.Cancer Res. 2020 Nov 1;80(21):4601-4609. doi: 10.1158/0008-5472.CAN-20-1830. Epub 2020 Aug 3. Cancer Res. 2020. PMID: 32747362 Free PMC article. Review.
-
PALB2 self-interaction controls homologous recombination.Nucleic Acids Res. 2012 Nov 1;40(20):10312-23. doi: 10.1093/nar/gks807. Epub 2012 Aug 31. Nucleic Acids Res. 2012. PMID: 22941656 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous